Gregory Daniel
Vice President, Head of Public Policy Innovation, Evidence, and Engagement, Eli Lilly and Company
Gregory Daniel is listed as Vice President, Head of Public Policy Innovation, Evidence, and Engagement, Eli Lilly and Company. Gregory spoke at ISPOR Europe 2026 in November 2026 (speaker, “Delay or Prepare? Navigating EU HTA in the Era of MFN-Driven Launch Uncertainty”). Speaks mainly at Government Administration events.
Compiled from published conference agendas; not yet confirmed by Gregory. Is this you? Claim this profile.
- Sector: Government Administration
About
Gregory Daniel, PhD, MPH is Vice President, Head of Policy Innovation, Evidence & Engagement at Eli Lilly and Company. Greg has led the Global Public Policy group, responsible for evaluating and developing public policy concepts in areas such as prescription drug access, affordability and innovation, global value-based healthcare, health equity, and other high priority policy areas. Greg also leads policy evidence development and external engagement, developing partnerships with academic groups, think-tanks, and other policy research organizations to advance policies that support innovation, access and affordability. He is also currently the Editor-in-Chief of Therapeutic Innovation and Regulatory Science (TIRS), the scientific journal of DIA. Greg also serves on the Board of Directors and is Past President for the Innovation in Value Initiative (IVI) Foundation, is Adjunct Associate Professor at the Eshelman School of Pharmacy at the University of North Carolina-Chapel Hill and is
Sessions at 1 conference
ISPOR Europe 2026 8 November 2026 – 11 November 2026
- Delay or Prepare? Navigating EU HTA in the Era of MFN-Driven Launch Uncertainty Speaker · 10 November 2026
Spoke alongside
People who have shared a session with Gregory at events on B2DB.
- Eric C Faulkner President/Founder · SymetryML 1 shared session
- Joerg Ruof 1 shared session
- Jon D Campbell Chief Science Officer · National Pharmaceutical Council 1 shared session
Others from Eli Lilly and Company
- Laurent Malherbe Executive Director 2 sessions
- Maroun Beyrouthy, Ph.D. Senior Advisor 2 sessions
- Ana Tanaka Associate Director Global Treasury 1 session
- Erin Johansson Director HEOR Obesity, International Value and Access 1 session
- Jenny Laird VP, Business Development - Neuroscience 1 session
- Khalil Asmar Vice President Cardiometabolic Health - Northern Europe 1 session
- Lotus Mallbris Senior Vice President - Head of Aesthetic Health 1 session
- Matthew Coghlan Vice President - External Innovation & Data Science - Diabetes Obesity & Cardiometabolic TA 1 session
- Michael Kopach, PhD Associate Vice President 1 session
- TiJuan Lumpkin Associate Vice President Collaboration & Mobility 1 session